ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!ENSC Company Profile and Key Details
Ensysce Biosciences, Inc.
ENSC Stock Price Chart
Stock Price Today
Ensysce Biosciences, Inc. (ENSC) stock declined over -2.04%, trading at $5.28 on NASDAQ, down from the previous close of $5.39. The stock opened at $5.49, fluctuating between $5.28 and $5.49 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Company Information
| Employees | 7 |
| Beta | 0.55 |
| Sales or Revenue | $2.23M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Ensysce Biosciences, Inc. (NASDAQ: ENSC) stock price is $5.28 in the last trading session. During the trading session, ENSC stock reached the peak price of $5.49 while $5.28 was the lowest point it dropped to. The percentage change in ENSC stock occurred in the recent session was -2.04% while the dollar amount for the price change in ENSC stock was -$0.11.
The NASDAQ listed ENSC is part of Biotechnology industry that operates in the broader Healthcare sector. Ensysce Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. David C. Humphrey C.P.A.
Chief Financial Officer, Sec. & Treasurer
Mr. David C. Humphrey CPA
Chief Financial Officer, Sec. & Treasurer
Dr. Jeffrey Millard Ph.d.
Chief Operating Officer
Mr. Richard Wright M.B.A., MSE
Chief Bus. Officer
Dr. Linda Pestano Ph.D.
Chief Devel. Officer
Dr. William K. Schmidt Ph.D.
Chairman of Clinical Advisory Board & Chief Medical Officer
Dr. D. Lynn Kirkpatrick Ph.D.
Pres, Chief Executive Officer & Director
Mr. Geoffrey Birkett
Chief Commercial Officer
ENSC's closing price is 154.85% higher than its 52-week low of $2.12 where as its distance from 52-week high of $14.67 is -63.26%.
Number of ENSC employees currently stands at 7.
Official Website of ENSC is: https://www.ensysce.com
ENSC could be contacted at phone 858 263 4196 and can also be accessed through its website. ENSC operates from 7946 Ivanhoe Avenue, La Jolla, CA 92037, United States.
ENSC stock volume for the day was 3.54K shares. The average number of ENSC shares traded daily for last 3 months was 88.2K.
The market value of ENSC currently stands at $6.89M with its latest stock price at $5.28 and 1.3M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com